Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

• Status: Recruiting
• Trial end date: 2022-12-01

Summary

DICE is a randomised study recruiting 126 women over 3 years from hospitals in the UK and Germany. Eligible patients will have tissue based diagnosis of advanced/recurrent ovarian cancer (clear cell, endometrioid or high grade serous or carcinosarcoma), have had chemotherapy before, and be platinum-resistant (the cancer has returned/grown significantly during or within 6 months of platinum-containing chemotherapy).

• Phase: Phase 2

Details

• Lead Sponsor: Imperial College London
• Collaborators: North Eastern German Society of Gynaecological Oncology; North Eastern Germany Society of Gynaecologic Oncology; Takeda Pharmaceuticals International, Inc.
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel